Immunostimulatory monoclonal antibodies for cancer therapy

Melero, Ignatio, Hervas-Stubbs, Sandra, Glennie, Martin, Pardoll, Drew M. and Chen, Lieping P. (2007) Immunostimulatory monoclonal antibodies for cancer therapy Nature Reviews Cancer, 7, (2), pp. 95-106. (doi:10.1038/nrc2051).


Full text not available from this repository.


Increasing immune responses with immunostimulatory monoclonal antibodies (mAbs) directed to immune-receptor molecules is a new and exciting strategy in cancer therapy. This expanding class of agents functions on crucial receptors, either antagonizing those that suppress immune responses or activating others that amplify immune responses. Complications such as autoimmunity and systemic inflammation are problematic side effects associated with these agents. However, promising synergy has been observed in preclinical models using combinations of immunostimulatory antibodies and other immunotherapy strategies or conventional cancer therapies. Importantly, mAbs of this type have now entered clinical trials with encouraging initial results

Item Type: Article
Digital Object Identifier (DOI): doi:10.1038/nrc2051
ISSNs: 1474-175X (print)
Related URLs:
Keywords: time, versus-host-disease, cancer, molecules, antigen-4 blockade, immune-responses, model, dendritic cells, phase-i trial, gene-therapy, immunotherapy, enhances antitumor immunity, monoclonal antibody, regulatory t-cells, responses, 4-1bb ligand, models, ctla-4 blockade, monoclonal-antibodies, metastatic melanoma
ePrint ID: 62840
Date :
Date Event
February 2007Published
Date Deposited: 11 Sep 2008
Last Modified: 16 Apr 2017 17:28
Further Information:Google Scholar

Actions (login required)

View Item View Item